KOSPIFood & Beverage001680

Daesang

₩17,110▲ 1.18%2026-11-18 close
Market Cap
₩592.8B
Turnover
₩1.2B
Volume
70K
Shares out.
34.7M
PER
—
PBR
0.6×
EPS
-₩8,795
Dividend Yield
5.07%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩850 per share · Prices as of the 2026-11-18 close

01

Report overview

Materials Recovery Pace Will Shape Daesang's Earnings Path

Food earnings are holding up, but the pace of recovery after the 2025 net loss attributable to controlling shareholders of KRW 304.2 billion depends on lysine-led materials.

  1. 1

    Annual revenue rose from KRW 4.08 trillion in 2022 to KRW 4.4 trillion in 2025, while operating profit peaked at KRW 176.9 billion in 2024 and eased to KRW 169.3 billion in 2025.

  2. 2

    The 2025 net loss attributable to controlling shareholders was KRW 304.2 billion, turning from profit to loss, and the debt ratio rose from 142.5% to 217.2%.

  3. 3

    Quarterly operating profit peaked at KRW 57 billion in the first quarter of 2026 before falling to KRW 46.5 billion in the second quarter and KRW 41.3 billion in the third, while net income attributable to controlling shareholders shrank to KRW 5.24 billion in the third quarter.

  4. 4

    Domestic lysine export volume rose 44.7% in January-September 2026, but the average export unit price fell 12.7%, so volume growth is offsetting weaker pricing.

  5. 5

    Because the company posted net losses over the last four quarters, the price-to-earnings ratio cannot be calculated, while the price-to-book ratio sits at a low level, so asset-based and earnings-based readings diverge.

02

Business structure

Daesang began with MSG sold under the Miwon brand and now runs two business lines, food and materials.

According to the 2025 annual report, the food segment generated KRW 3.82 trillion in sales and the materials segment KRW 1.46 trillion, with KRW 876.4 billion of sales adjustments deducted to reach consolidated revenue of KRW 4.4 trillion.

The food segment sells seasonings, soy-based condiments, kimchi and side dishes, and frozen foods under brands such as Cheongjeongwon, Miwon and Jongga, and overseas food sales under Jongga and Cheongjeongwon are described as stable.

Overseas production and sales run through subsidiaries in Indonesia, Vietnam and the United States. The materials segment consists of starch and starch sugars made from corn and tapioca, and bio products such as lysine, arginine and tryptophan, and press reports put this business at roughly 30% of total sales.

Lysine is a commodity amino acid supplied to feed producers worldwide, and its profitability swings sharply with international prices. Daesang developed lysine domestically in 1973, sold the unit in 1988 and regained it in 2015, and it has run the business since.

A bio plant in Gunsan started production in October 2025, and the company is widening its range into higher-value amino acids for supplements, medical foods and pharmaceutical ingredients. Its customers are consumers in food and feed and food-processing companies in materials.

In lysine, domestic rivals such as CJ Cheiljedang and Chinese producers are the main competitors, and the key variable for materials earnings is the oversupply from Chinese producers that keeps prices under pressure.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.1T₩50.9B4.4%
2025Q4₩1T₩20.3B1.9%
2026Q1₩1.1T₩57B5.1%
2026Q2₩1.2T₩46.5B4.0%
2026Q3₩1.2T₩41.3B3.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩4.1T₩140B₩83.1B3.4%6.4%141.2%
2023₩4.1T₩123.7B₩67.1B3.0%5.1%148.1%
2024₩4.3T₩176.9B₩95.2B4.2%6.7%142.5%
2025₩4.4T₩169.3B-₩304.2B3.8%−28.4%217.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual revenue rose from KRW 4.08 trillion in 2022 to KRW 4.11 trillion in 2023 (up 0.6% year on year), KRW 4.26 trillion in 2024 (up 3.6%) and KRW 4.4 trillion in 2025 (up 3.4%), marking three consecutive years of growth from 2023 through 2025, with 2025 the largest year of 2022 to 2025.

Operating profit went from KRW 140 billion in 2022 to KRW 123.7 billion in 2023 (down 11.6%), then rose to KRW 176.9 billion in 2024 (up 43.0%), the largest year in the period, before easing to KRW 169.3 billion in 2025 (down 4.3%).

The operating margin was 3.4% in 2022, 3.0% in 2023, 4.2% in 2024 and 3.8% in 2025, so margins stayed in the 3% to 4% range despite revenue growth.

Net income attributable to controlling shareholders fell from KRW 95.2 billion in 2024 (up 41.9%) to a net loss of KRW 304.2 billion in 2025, which turned the result from profit to loss, while the net loss including non-controlling interests was KRW 303.1 billion.

Operating profit of KRW 169.3 billion was positive, yet the bottom line swung deeply into loss, which points to a heavy burden from items below operating profit; the item-level breakdown needs to be checked in the notes to the annual report.

The debt ratio rose from 142.5% in 2024 to 217.2% in 2025, and at the end of 2025 total equity was KRW 1.1 trillion, of which KRW 1.07 trillion belonged to controlling shareholders, against total liabilities of KRW 2.38 trillion.

Operating cash flow went from negative KRW 90.9 billion in 2022 to KRW 374.8 billion in 2023, KRW 187.7 billion in 2024 and KRW 188.1 billion in 2025, staying positive since 2023.

Quarterly revenue hit a low of KRW 1.05 trillion in the fourth quarter of 2025 (down 8.4% from the prior quarter) and then rose for three consecutive quarters to KRW 1.18 trillion in the third quarter of 2026.

Operating profit peaked at KRW 57 billion in the first quarter of 2026 (up 180.7% from the prior quarter) after KRW 20.3 billion in the fourth quarter of 2025, then fell for two consecutive quarters to KRW 46.5 billion and KRW 41.3 billion, with the third quarter down 18.9% year on year.

Net income attributable to controlling shareholders was KRW 32 billion, KRW 18.5 billion and KRW 5.24 billion in the first three quarters of 2026, after a net loss of KRW 372.6 billion in the fourth quarter of 2025, and the trailing four-quarter net loss attributable to controlling shareholders totaled KRW 316.8 billion.

According to a report on first-quarter 2026 results, operating profit in the materials segment fell 67.7% to KRW 7.5 billion while the food segment rose 13.7% to KRW 38.2 billion, so earnings relied more heavily on food.

05

Industry analysis

Lysine is a commodity amino acid used as a feed additive, so on the supply side the capacity expansion of Chinese producers sets prices. Chinese lysine capacity rose 94% from 2.01 million tonnes in 2019 to about 3.9 million tonnes in 2025, accounting for roughly 76% of global capacity.

Meihua, one of the largest producers, expanded its annual capacity to 1.6 million tonnes this year.

Under this structure prices are weak, yet Korean export volumes are rising: lysine export volume reached 100,126 tonnes in January to September 2026, up 44.7% year on year, and export value rose 26.3% to USD 125.57 million.

Over the same period the average export unit price fell 12.7%, from USD 1,437 to USD 1,254 per tonne. On the demand side, higher soybean meal prices make it easier for feed producers to add amino acids such as lysine, according to some analysts.

On the regulatory side, the European Union imposed anti-dumping duties of up to 58.2% on Chinese lysine in 2025 and started a review in April 2026 on whether the duties are being offset by price cuts, and the United States has also put duties on Chinese lysine in effect.

CJ Cheiljedang reported that its core materials business operating profit rose from KRW 6 billion in the fourth quarter of 2025 to KRW 37.3 billion in the first quarter of 2026, KRW 113.4 billion in the second quarter and KRW 108.5 billion in the third quarter.

Against the same lysine cycle, Daesang's materials operating profit fell 67.7% in the first quarter, which shows a clear gap in how fast companies are recovering. Daesang's own explanation emphasizes a base effect from last year's anti-dumping benefit and weaker demand for starch sugars.

06

Outlook

The company attributed the rise in lysine exports in January to September 2026 to wider exports to Europe and North America and a recovery in soybean meal prices. The key checkpoint for the materials segment is the direction of average lysine selling prices.

Market commentary treats a turnaround in materials as the main lever for earnings and share price recovery. Chinese lysine inventories in Europe are falling, and the start of US duties on Chinese lysine is expected to lift average selling prices.

Still, first-half 2026 materials sales rose 2.1% to KRW 26.5 billion... specifically, sales were KRW 826.5 billion, up 2.1%, while operating profit fell 35.7% to KRW 31.5 billion, reflecting a base effect from strong lysine prices a year earlier and weaker starch sugar demand.

Whether lysine market conditions recover in the second half is therefore the biggest variable for a rebound.

The food segment continues to post steady sales under the Jongga and Cheongjeongwon brands, and its operating profit rose 13.7% to KRW 38.2 billion in the first quarter of 2026, partly offsetting weakness in materials.

The Gunsan bio plant began production in October 2025 and is widening its market reach in the United States and Europe through flavor companies, and the company has stated a goal of strengthening its materials position in North and Latin America.

The next checkpoints are the materials sales and operating profit in the 2026 annual report and the outcome of the EU anti-dumping review.

07

Valuation

PER
—
PBR
0.6×
ROE
-25.5%
EPS
-₩8,795
BPS
₩29,259
Dividend per share
₩850

The price-to-book ratio sits at a low level, meaning the share price is well below book value per share on an asset basis.

By contrast, the price-to-earnings ratio cannot be calculated because net income attributable to controlling shareholders totaled a loss of KRW 316.8 billion over the last four quarters, so earnings-based multiples do not apply at this stage.

Whether dividends can be sustained after the 2025 net loss is a point to watch, and with the debt ratio at 217.2%, financial flexibility has narrowed compared with earlier years.

Net income attributable to controlling shareholders fell from KRW 32 billion in the first quarter of 2026 to KRW 18.5 billion in the second and KRW 5.24 billion in the third, which shows that the margin of profitability is thinning.

Within the food sector, some listed companies have earnings-based multiples and others do not, which limits the usefulness of simple multiple comparisons. A balanced reading pairs the share price relative to assets with the durability of the earnings recovery.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Signs of improving lysine supply and demand

Domestic lysine export volume rose 44.7% in January to September 2026, and higher soybean meal prices have improved conditions for feed makers to use more amino acids. EU anti-dumping duties on Chinese lysine and US duties on Chinese goods are cited as factors that could slow the oversupply. If materials operating profit recovers, a scenario of stronger earnings capacity becomes plausible.

A profit base in the food segment

Food segment operating profit rose 13.7% year on year to KRW 38.2 billion in the first quarter of 2026. Stable domestic and overseas sales under the Jongga and Cheongjeongwon brands partly offset weakness in materials. Cost improvements and more efficient promotions are cited as drivers of better profitability.

A turn in quarterly profit direction

Operating profit of KRW 57 billion in the first quarter of 2026 recovered sharply from KRW 20.3 billion in the fourth quarter of 2025. After the fourth-quarter 2025 loss, net income attributable to controlling shareholders was positive in each of the first three quarters of 2026. Revenue rose for three consecutive quarters from the fourth-quarter 2025 low through the third quarter of 2026.

09

Bear factors

Oversupply from Chinese producers

Chinese lysine capacity reached about 3.9 million tonnes in 2025, roughly 76% of global capacity. Average domestic export unit prices fell 12.7% year on year in January to September 2026. Because volume gains are only partly offsetting price declines, higher exports do not translate directly into higher profit.

Sharp decline in materials profit

Materials operating profit fell 67.7% year on year to KRW 7.5 billion in the first quarter of 2026, and first-half 2026 materials operating profit fell 35.7% to KRW 31.5 billion. The company attributes this to a base effect from strong lysine prices a year earlier and weaker starch sugar demand. Quarterly operating profit has declined for two consecutive quarters since the second quarter of 2026.

Rising financial burden

The debt ratio rose from 142.5% in 2024 to 217.2% in 2025. Total liabilities at the end of 2025 were KRW 2.38 trillion, against total equity of KRW 1.1 trillion.

A net loss attributable to controlling shareholders of KRW 372.6 billion in the fourth quarter of 2025 pushed the trailing four-quarter total to KRW 316.8 billion.

10

Risk factors

Raw materials and regulatory risk

Raw material prices for soybean meal, corn and tapioca affect both costs and selling prices of lysine and starch sugars. Anti-dumping and tariff measures in the EU and the United States could change import competition depending on their outcome.

If the EU review started in April 2026 finds that duty effects are being offset, expectations for higher European prices could weaken.

Financial structure and dividend capacity

The 2025 net loss attributable to controlling shareholders pushed the debt ratio up to 217.2%, narrowing financial flexibility. Keeping dividends intact requires both a return to net profit and sustained cash generation.

Operating cash flow has stayed positive since 2023, but whether the 2025 loss was one-off or recurring still needs to be confirmed.

Concentrated capacity and new market access

The 2025 annual report records a lysine average utilization rate of 102.6%, meaning capacity is already running at a high level. Further volume growth would require investment and new sales channels, and weak prices could delay returns on that spending.

Whether high-value amino acids from the Gunsan bio plant expand in North America and Europe as planned is the key question.

11

What to watch next

  1. Early 2027 (2026 fourth-quarter preliminary results)

    Check whether the lysine price recovery continued into the fourth quarter and whether materials operating profit held near the third-quarter 2026 level. Preliminary results precede the periodic report and should be read separately from audited figures.

  2. Around late March 2027 (2026 annual report filing)

    Review full-year 2026 operating profit, materials segment sales and utilization rates. The timing reflects the prior annual report, filed on March 27, 2026. Also check how the 217.2% debt ratio at the end of 2025 has changed.

  3. After November 2026 (announcement date not fixed)

    Watch the outcome of the EU review of anti-dumping duties on Chinese lysine. The result will shape European selling prices and the competitive pressure from Chinese imports.

  4. Around late April 2027 (first-quarter 2027 results)

    Check whether materials operating profit recovers from the KRW 7.5 billion level in the first quarter of 2026, and whether food operating profit holds near KRW 38.2 billion.

12

Overall view

Daesang's revenue grew from 2022 through 2025, but its operating margin stayed in the 3% to 4% range, and the company swung to a net loss attributable to controlling shareholders of KRW 304.2 billion in 2025.

Quarterly operating profit peaked at KRW 57 billion in the first quarter of 2026 and then declined in the second and third quarters, and net income attributable to controlling shareholders shrank to KRW 5.24 billion in the third quarter.

Materials profit fell sharply in the first quarter, despite a 44.7% rise in lysine export volume, because average export prices dropped and last year's base effect weighed, while the food segment's 13.7% profit increase cushioned the group.

Oversupply from Chinese producers persists, and EU and US trade measures and a recovery in soybean meal prices are cited as possible support. On the financial side, the debt ratio rose to 217.2%, so dividend and investment capacity merit close review.

The checkpoints that matter next are the preliminary fourth-quarter 2026 results, the 2026 annual report and the outcome of the EU anti-dumping review.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. securities.miraeasset.com
  2. mitrade.com
  3. files-scs.pstatic.net
  4. finance.thesmileinfo.com
  5. hanaw.com
  6. file.myasset.com
  7. bondweb.co.kr
  8. kr.investing.com
  9. financedailycare.com
  10. myasset.com
  11. m.news.nate.com
  12. newsway.co.kr
  13. kind.krx.co.kr
  14. news.nate.com
  15. m.news.nate.com
  16. topdaily.kr
  17. biz.newdaily.co.kr
  18. ilovepc.co.kr

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis